Christine Lovly
-
October 20, 2016
VICC trial putting lung cancer therapy to the test
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. -
June 22, 2016
Lovly tapped to brief Congress on cancer research
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science. -
May 26, 2016
Precision medicine already changing cancer treatment strategies
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. -
January 21, 2016
Lovly lands cancer research grant from V Foundation
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been awarded a V Scholar Grant from the V Foundation for Cancer Research. -
January 14, 2016
VICC helps expand cancer patient’s treatment options
Edward (Ned) Wikle recently celebrated the Christmas holidays with his wife and three young children, a celebration the Jackson, Mississippi-based endodontist, U.S. Navy veteran and cancer patient wasn’t sure he would have. -
March 12, 2015
Gene mutations may predict melanoma response to immunotherapies
Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators. -
September 4, 2014
Lung cancer study reveals new drug combination targets
A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.